Maxwell Biosciences, founded in 2016, is a preclinical-stage drug platform firm that is actively developing an all-new CLAROMER™ biotechnology platform that creates proprietary, virucidal, smaller molecule, non-peptide chemicals known as peptoids.
This novel biotechnology emulates the power and flexibility of natural antimicrobial peptides while delivering pharmacological benefits of a small molecule. The organization is led by a group of distinguished scientists and executives.
U.S. government-funded labs recently confirmed that a study evaluating the virucidal activity of Maxwell’s lead drug candidate has shown direct virucidal efficacy against SARS-CoV-2.
Maxwell’s drugs appear to have a wide therapeutic window in humans, according to recent live mouse safety data from Texas A&M.
Before this, Maxwell’s drugs have been found to show direct activity against the structure of the Herpes Simplex Virus (HSV-1).
Maxwell Pharmaceuticals, Inc.’s drug platform is bolstered by a granted patent portfolio that gives it a significant advantage in the fight against emerging viral pandemics.